Company / R&D Expense
Bionano Genomics, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$11.4M
FY2025
5-year range
$11.4M / $54.0M
FY2021-FY2025
Trend
-54.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $54M to $11M over the past 2 years.
Based on SEC 10-K filings.
$11M in FY2025 with a 5-year CAGR of +2.1%.
Declined from $54M to $11M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -38.6%
- 5-Year CAGR
- +2.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +2.1%, indicating consistent growth.
- In FY2025, r&d expense decreased 54.1% year-over-year.
- Peak r&d expense was recorded in FY2023.
- Lowest r&d expense in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -8.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.4M | -54.1% |
| FY2024 | $24.8M | -54.1% |
| FY2023 | $54.0M | +10.2% |
| FY2022 | $49.0M | +118.1% |
| FY2021 | $22.5M | +119.2% |
| FY2020 | $10.3M | +12.9% |
| FY2019 | $9.1M | -4.3% |
| FY2018 | $9.5M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 22, 2026